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Cetrorelix, a luteinising hormone-releasing hormone (LHRH) analogue, has been shown to limit growth of the human androgen-
independent prostate cell line DU-145, although other inhibitory actions may also be affected. Both growth and invasion of DU-145
cells are linked to autocrine epidermal growth factor receptor (EGFR) signalling. Invasiveness requires not only cells to migrate to
conduits, but also reduced adhesiveness between tumour cells to enable separation from the tumour mass. Thus, we investigated
whether Cetrorelix alters the DU-145 cell–cell adhesion and if this occurs via altered EGFR signalling. Pharmacologic levels of
Cetrorelix limited the invasiveness of a highly invasive DU-145 subline overexpressing full-length EGFR (DU-145 WT). Extended
exposure of the cells to Cetrorelix resulted in increased levels of the cell–cell adhesion complex molecules E-cadherin, a- and b-
catenin, and p120. Puromycin blocked the increases in E-cadherin and b-catenin levels, suggesting that de novo protein synthesis is
required. The Cetrorelix effect appears to occur via transmodulation of EGFR by a protein kinase C (PKC)-dependent mechanism, as
there were no changes in DU-145 cells expressing EGFR engineered to negate the PKC transattenuation site (DU-145 A654);
downregulation of EGFR signalling produced a similar upregulation in adhesion complex proteins, further suggesting a role for
autocrine signalling. Cetrorelix increased the cell–cell adhesiveness of DU-145 WT cells to an extent similar to that seen when
autocrine EGFR signalling is blocked; as expected, DU-145 A654 cell–cell adhesion also was unaffected by Cetrorelix. The increased
adhesiveness is expected as the adhesion complex molecules moved to the cells’ periphery. These data offer direct insight into the
possible crosstalk pathways between the LHRH and EGFR receptor signalling. The ability of Cetrorelix to downregulate EGFR
signalling and subsequently reverse the antiadhesiveness found in metastatic prostate cancer highlights a novel potential target for
therapeutic strategies.
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Adhesion between normal epithelial cells is usually strong and
stable, limiting cell movement. In carcinomas, these tight cell
associations must first be disrupted or prevented from forming
before tumour cells are able to disseminate and metastasise. Cell–
cell association is often disorganised in tumours, and has been
linked to tumour invasiveness and metastasis (Pignatelli and
Vessey, 1994; Shino et al, 1995; Richmond et al, 1997). Acquisition
of invasive potential by malignant cancer cells results from an
accumulation of characteristics, including increased cell motility,
secretion of proteolytic enzymes, and alterations of cell–substrate
and cell–cell adhesion (Fidler, 2003; Grunert et al, 2003). The
molecular mechanisms responsible for this latter process, altered
cell–cell adhesion, in invasive cancer cells are poorly understood
(Comoglio and Trusolino, 2002). However, the net result is a
reduction in cadherin/catenin complexes at the cells’ periphery
(Morita et al, 1999; Davies et al, 2000). Thus, to better understand
the mechanisms of tumour cell dissociation, the role of cadherins
must be taken into account, as they are crucial in cell–cell
adhesion (Takeichi, 1993; Kim et al, 1999; Suyama et al, 2002).
Cadherins comprise a family of transmembrane cell surface
glycoproteins that mediate calcium (Ca
2þ)-dependent, homotypic
cell–cell interactions through their extracellular domains, and
regulate a variety of biological processes during development,
morphogenesis, and tumour metastasis (Gumbiner, 1996; Yap et al,
1997; Conacci-Sorrell et al, 2002). Ca
2þ-dependent cell–cell
adhesion usually consists of rapid localisation of surface E-
cadherin molecules to the regions of contact, resulting in
homotypic binding that fosters the maintenance of normal cellular
structure. However, metastatic cancer cells are able to over-ride or
avoid contact inhibition signals employed by normal epithelial
cells to control proliferation and cell movement.
The linkage between E-cadherin and the cellular cytoskeleton is
a complex interaction involving a number of structural and
signalling cytoplasmic proteins such as a- and b-catenin and p120
(Van Aken et al, 2001; Mason et al, 2002). Early studies identified
Received 9 July 2004; revised 17 November 2004; accepted 1 December
2004; published online 18 January 2005
*Correspondence: Dr T Turner; E-mail: turner@tuskegee.edu
British Journal of Cancer (2005) 92, 366–375
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sE-cadherin/catenin interactions as imperative for cell–cell adhe-
sion (Chitaev and Troyanovsky, 1998). b-Catenin binds with high
affinity to the carboxyl-terminal region of the cadherin cytoplas-
mic tail, while a-catenin serves as an anchor, by bridging to a-
actinin, to link the complex to the actin cytoskeleton (Aberle et al,
1994; Hulsken et al, 1994; Funayama et al, 1995; Jou et al, 1995;
Rimm et al, 1995). These molecules not only play structural roles
but also alter cell responses and phenotypes. b-Catenin is also
found to immunoprecipitate with the APC tumour suppressor
protein (Su et al, 1993; Hulsken et al, 1994; Shibata et al, 1994),
and has been recently identified as an oncogene (Kim et al, 2002;
Minamoto et al, 2002; Kielhorn et al, 2003; Schneider et al, 2003).
It is also central to cell signalling, as upon dissociation from
E-cadherin, it transits to the nucleus to alter transcriptional
profiles (Mason et al, 2002; van de Wetering et al, 2002). A
reduction in b-catenin expression decreases the stability of the
adhesion complex and likely results in impairment in E-cadherin
function (Willert and Nusse, 1998; Lowy et al, 2002; Mason et al,
2002). Similarly, a reduction in E-cadherin often results in
b-catenin degradation (Liu et al, 2002). Another protein associated
with E-cadherin, p120 (Thoreson et al, 2000), is phosphorylated on
both tyrosine and serine residues in response to a variety of growth
factors such as epidermal growth factor (EGF), platelet-derived
growth factor (PDGF), and colony stimulating factor (CSF)-1,
suggesting involvement in active signalling (Downing and
Reynolds, 1991; Shibamoto et al, 1995). Thus, cell–cell adhesion
serves not only a structural role but dictates cellular behaviour.
As carcinomas progress to the invasive and metastatic stages,
select adhesive epithelial cells usually undergo a mesenchymal-like
transition that enables their movement from the primary tumour
mass (Comoglio and Boccaccio, 2001; Conacci-Sorrell et al, 2002).
During this process in breast, gastric, and pancreatic metastatic
carcinomas, E-cadherin expression is frequently downregulated or
even undetectable (Birchmeier and Behrens, 1994; Lowy et al,
2002). This pattern of E-cadherin expression also persists in
disseminated prostate carcinomas when compared to nonmeta-
static prostate cells (Umbas et al, 1992; Davies et al, 2000; Mason
et al, 2002). In addition, the loss of E-cadherin expression has been
shown as a consequence of autocrine activation of epidermal
growth factor receptor (EGFR) signalling (Jawhari et al, 1999). This
combination of autocrine EGFR signalling and loss of E-cadherin
expression leads to cell proliferation, dedifferentiation, and
induction of cell motility (Hazan and Norton, 1998). Such an
association has been suggested in the progression of breast
carcinoma cells to a more invasive phenotype, which correlates
with downregulation of E-cadherin and overexpression of EGFR
(Sorscher et al, 1995a,b; Hazan and Norton, 1998). On a molecular
level, EGFR signalling leads to tyrosine phosphorylation of the
catenin complex with subsequent breakdown of cell adhesion
(Shiozaki et al, 1995; Jawhari et al, 1999; Mariner et al, 2004).
In this study, we examined whether the beneficial anticancer
effects of Cetrorelix include effects in addition to the established
antiproliferative effects. Luteinising hormone-releasing hormone
(LHRH) receptors have increased expression in many cancers
compared to normal cells (Emons et al, 1998; Schally et al, 2001;
Straub et al, 2001), with increased expression in benign prostate
hyperplasia (BPH) as well (Straub et al, 2003). The presence of
these receptors enables LHRH analogues to affect directly prostate
tumour cells (Qayum et al, 1990; Halmos et al, 2000) in addition to
the indirect central androgen suppression. In addition, it has been
shown that LHRH agonists directly inhibit cell proliferation of
DU-145 and LNCaP prostate cancer cell lines (Dondi et al, 1994,
1998; Limonta et al, 2001). In line with these observations, the
LHRH analogue Cetrorelix has been shown to have direct
antiproliferative actions on DU-145 cells (Jungwirth et al,
1997b). As a consequence of this exposure, LHRH analogues have
caused decreased levels of EGFR expression (Moretti et al, 1996;
El-Bahrawy and Pignatelli, 1998; Lamharzi et al, 1998).
Previously, we have shown that DU-145 WT, a subline of the
human prostate carcinoma cell line DU-145, presents autocrine
EGFR signalling that is critical to both cell proliferation and
invasion (Xie et al, 1995; Turner et al, 1996). Recently, we
demonstrated under both in vivo and in vitro conditions that a
LHRH agonist inhibited enhanced invasiveness of EGFR-dependent
proliferation in DU-145 WT through interference with EGFR
signalling (Wells et al, 2002). Therefore, these data taken together
lead us to hypothesise that the LHRH analogue Cetrorelix would
abrogate EGFR signalling. This abrogation would in turn decrease
phosphorylation of the associated catenins, thus leading to
upregulation of the cell adhesion molecule E-cadherin, which
may ultimately result in inhibition of prostatic tumour progression.
MATERIALS AND METHODS
Materials
The LHRH analogue Cetrorelix ((Ac-D-Nal (2)
1, D-Phe (4Cl)
2,
D-Pal (3)
3, D-Cit
6, D-Ala
10) LH-RH) was obtained from ASTA
Medica (Frankfurt/Main, Germany) and dissolved in serum-free
Dulbecco’s modified Eagle’s medium (DMEM). The primary
antibodies used were mouse monoclonal antibodies to E-cadherin,
a- and b-catenin, and p120 (Transduction Laboratories, California,
USA), phosphorylated MARCKS (Cell Signaling, Massachusetts,
USA), phosphorylated EGFR (Cell Signaling, Massachusetts, USA),
and EGFR (Zymed Laboratories, California, USA). FITC-conju-
gated secondary antibodies were obtained from BD Biosciences
(California, USA). Secondary antibodies for the immunofluores-
cence were obtained from Molecular Probes (Oregon, USA).
Inhibitors included the EGFR-specific tyrosine kinase inhibitor
PD153035 (CalBiochem, California, USA), monoclonal antibody
(528) EGFR (Oncogene, Massachusetts, USA), EGFR siRNA
(Upstate, Virginia, USA), and the transcriptional and translational
inhibitor puromycin (Sigma, Missouri, USA). Other reagents were
obtained from Sigma.
DU-145 cell lines
The cell line DU-145 was originally derived from a brain metastasis
of a human prostate adenocarcinoma (Stone et al, 1978); it retains
the androgen independence of the original tumour and does not
express a functional androgen receptor (Dondi et al, 1998). This
cell line possesses both LHRH and EGF receptors and produces
EGFR ligands TGF-a and EGF (Xie et al, 1995; Jungwirth et al,
1997a). We have expressed exogenously encoded EGFR in DU-145
cells (Xie et al, 1995). Utilising established protocols, DU-145 cells
were transfected by retroviral-containing EGFR constructs (Wells
et al, 1990). The wild-type (WT) EGFR construct is a full-length
cDNA derived from a placental cDNA library. Cells expressing WT
EGFR at levels that escape downregulation demonstrate enhanced
invasiveness in vitro (Xie et al, 1995) and in vivo (Turner et al,
1996).
The DU-145 WT subline expresses EGFRs that are phosphory-
lated and negatively modulated by protein kinase C (PKC); thus,
we have generated an additional DU-145 subline that is not
negatively modulated by PKC (Wells et al, 2002). This subline is
identical to DU-145 WT except that it contains a full-length EGFR
in which the target site for PKC phosphorylation, amino-acid
threonine 654 (T654), has been replaced with alanine (DU-145
A654) by site-directed mutagenesis; this construct is resistant to
PKC phosphorylation and negative transmodulation (Welsh et al,
1991; Chen et al, 1996).
The DU-145 WT and A654 cells were maintained in DMEM
(4.5gml
 1 glucose) (Cellgro, Virginia, USA) containing 10% FBS
and supplemented with L-glutamine (2mM), penicillin/strepto-
mycin (100Uml
 1), nonessential amino acids (0.1mM), and
Signalling mechanism of hormonal therapy in prostate cancer
C Yates et al
367
British Journal of Cancer (2005) 92(2), 366–375 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
ssodium pyruvate (1mM) (371C, 90% humidity, 5% CO2 and 95%
air). For stable selection of WT or A654 EGFR, cells were grown in
G418 (1000mgml
 1) (Gibco, New York, USA), although all
experiments were performed in the absence of G418.
Invasion assay
Cell invasiveness in vitro was determined by the ability of cells to
transmigrate a layer of extracellular matrix, Matrigel, in a Boyden
Chamber assay. Matrigel invasion chamber plates were obtained
from Becton Dickinson Labware (Bedford, Massachusetts, USA). A
total of 20000 cells were plated in the Matrigel-containing chamber
in serum-free media containing 1% BSA for the first 24h; this was
then replaced with Cetrorelix serum-free media for the remaining
24h. Enumeration of the cells that invaded through the matrix
over a 48h period was accomplished by visually counting cells on
the bottom of the filter. All experiments were performed in
triplicate chambers.
Flow cytometry
Cells (3 10
5) were grown for 2 days or to 80% confluency in
60mm plates. The LHRH analogue Cetrorelix (10
 5 M) was added
for time intervals of 6, 12, and 24h and compared to diluent alone.
Samples were washed with PBS and fixed with paraformaldehyde,
and permeabilised with 1% Triton X-100. Samples were blocked
with 5% BSA and incubated with the appropriate FITC-conjugated
primary antibody or primary antibody (anti-EGFR, anti-E-
cadherin, anti-a-catenin, anti-b-catenin, and anti-p120) at 371C
for 1h. For unconjugated samples, FITC-conjugated secondary
antibody was added. Fluorescence was measured by a flow
cytometer (Coulter, Florida, USA).
Immunoblotting
Cells (3 10
5) were grown for 2 days or to 80% confluency in six-
well plates. The LHRH analogue Cetrorelix (10
 5 M) was incubated
for 6, 12, and 24h time intervals and compared to diluent alone.
Protein lysates were prepared from cultured cells in the following
buffer: 50mM Tris, pH 7.5, 120mM NaCl, 0.5% Nonidet P-40, 40mM
phenylmethylsulphonylfluoride (PMSF), 50mgml
 1 leupeptin, and
50mgml
 1 aprotinin (all from Sigma). Cells were allowed to lyse
for 1h on ice; the lysed cell solution was centrifuged and the
resulting supernatants were extracted and quantitated using a
Bradford assay. Protein lysates (30mg) were separated by 7.5%
SDS–PAGE, immunoblotted, and analysed using chemilumines-
cence (Amersham Biosciences, New Jersey, USA). Primary
antibodies used included anti-EGFR (Zymed Diagnostics, Califor-
nia, USA), anti-E-cadherin, anti-b-catenin, and anti-p120 (Trans-
duction Laboratories, Kentucky, USA), and anti-a-catenin (Santa
Cruz Biotechnology, California, USA). The staining was visualised
by a secondary anti-mouse IgG or anti-rabbit antibody linked to
horseradish peroxidase (Promega, Wisconsin, USA).
siRNA for EGFR
A total of 2 10
5 cells were plated in six-well plates equalling
60–70% confluency. The EGFR siRNA (160pmol) was diluted in
200ml of Opti-MEM (Invitrogen, California, USA). A 4ml portion of
Lipofectamine 2000 (Invitrogen, California, USA) was diluted in
200ml of Opti-MEM and incubated for 5min at room temperature.
The diluted siRNA and Lipofectamine 2000 were mixed and
incubated for 20min at room temperature. Complexes were added
to each well and incubated for 24h. Media were changed and
incubated for an additional 24h. Cells were lysed according to
established protocols.
Immunofluorescence microscopy
A total of 3 10
5 cells were grown for 2 days or to 80% confluency
on glass coverslips and then treated with or without Cetrorelix
(10
 5 M) and compared to diluent alone. Cells were then fixed in
4% paraformaldehyde, permeabilised with 100mM Tris-HCl pH
7.4, 150mM NaCl, 10mM EGTA, 1% Triton X-100, 1mM PMSF, and
50mgml
 1 aprotinin (all from Sigma), and subsequently blocked
with 5% BSA for 1h at room temperature. Samples were incubated
with indicated primary antibodies diluted in blocking buffer at 41C
overnight. FITC-conjugated secondary antibody was then added
(BD Biosciences, California, USA). Cells were then stained with
propidium iodine for nuclear staining. Cells were analysed with
laser confocal microscopy using a Leica TCSNT 3 laser 4 PMT
system (Olympus, New York, USA).
Cell aggregation assay
Calcium-dependent aggregation of the DU-145 sublines was
measured as previously described by Takeichi (1995) with the
following modifications. Cell monolayers grown to 80% confluence
were incubated for 24 or 48h in 10% FBS in DMEM with or
without 10
 5 M Cetrorelix. Cell monolayers were detached from the
culture dishes by incubating in cell stripper (Cell Gro, Virginia,
USA) for 5–10min at 371C. Any remaining cells were detached
using a rubber policeman, washed once with PBS, and collected by
centrifugation. Cells were resuspended in 10% FBS in DMEM and
single-cell suspensions made by trituration with a Pasteur pipette.
Cell number was determined in the Coulter Counter Z1 (Coulter,
Florida, USA). Cells were plated in triplicate wells of a 24-well plate
at 2 10
5cellswell
 1 in 10% FBS in DMEM with 1mM CaCl2 and
allowed to aggregate for 60min on a gyratory shaker at 80r.p.m. at
371C. Assays were stopped at 0 and 60min by fixing the cells in
0.5% paraformaldehyde. The extent of cell–cell binding was
monitored by measuring the disappearance of single cells using the
Coulter Counter Z1. The index of the degree of aggregation was
measured utilising the formula 100 (N0/N60), where N0 is the
total cell number per well and N60 is the total number of particles
after 60min of incubation as determined by counting in a Coulter
Counter Z1.
Statistical analysis
Statistics for all experiments were performed using the Sigma Plot
statistical program (Jandel Scientific, California, USA). Indepen-
dent Student’s t-test was utilised to determine a statistical
difference between experimental and the controls for individual
experiments.
RESULTS
The LHRH analogue Cetrorelix decreases invasion in
DU-145 sublines
To confirm and extend the inhibitory effects of Cetrorelix on
prostate carcinomas, we utilised a genetically engineered human
androgen-independent prostate carcinoma cell line that over-
expresses a full-length EGFR, DU-145 WT. This subline is highly
invasive in response to upregulation of autocrine EGFR signalling
(Xie et al, 1995; Turner et al, 1996) that exists in practically all
prostate carcinomas (Kim et al, 1999). In determining the utilised
dose of Cetrorelix, we selected the pharmacologic dose of 10
 5 M
based on literature reports for Cetrorelix (Tang et al, 2002) and a
related LHRH analogue goserelin (Dondi et al, 1994; Jungwirth
et al, 1997a,b; Limonta et al, 1998; Wells et al, 2002). In addition,
growth studies from our laboratory utilising Cetrorelix at 10
 5 M
inhibited DU-145 WT proliferation without causing cell death
(data not shown).
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prostate cancer progression, we determined whether invasion
was abrogated. Cetrorelix exposure reduced the invasiveness of the
DU-145 WT sublines through a Matrigel barrier from 100% down
to 23714% (Figure 6; n¼4, Po0.05). This level of inhibition is
comparable to the decreases noted when either EGFR motility
signalling via PLCg or calpain signalling is abrogated (Xie et al,
1995; Turner et al, 1996; Kassis et al, 1999; Mamoune et al, 2003).
Cetrorelix increases levels of cell adhesion molecules
To determine the effectiveness of Cetrorelix treatment on altering
protein expression levels, we measured EGFR, E-cadherin, and its
associated adhesion molecules (a- and b-catenins, and p120) by
flow cytometry. After 6h of Cetrorelix exposure, EGFR levels were
significantly reduced in DU-145 WT cells when compared to
nontreated, control levels. This significant reduction in EGFR
levels continued throughout the 24h experimental time period
(Figure 1A; Po0.05). While Cetrorelix decreased EGFR surface
expression, it induced an increase in E-cadherin levels (Figure 1B).
Likewise, the E-cadherin-associated molecules a-catenin, b-cate-
nin, and p120 also demonstrated a continual increase in their
expression, with all showing significant increases after 24h of
Cetrorelix exposure (Figure 1C–E; Po0.05%). To confirm results
obtained from the flow cytometry experiments, we immunoblotted
for whole-cell protein content of total EGFR and adhesion
molecules E-cadherin and b-catenin. Again a similar pattern
was seen, with a reduction in EGFR levels and an increase in
E-cadherin and b-catenin levels (data not shown).
To thoroughly examine if the increases in protein and
expression levels of E-cadherin and b-catenin were associated
with upregulation in transcription, we used the protein synthesis
inhibitor puromycin. Puromycin exposure was able to block
completely the enhanced ability of Cetrorelix to restore the
E-cadherin and b-catenin expression levels (Figure 2).
Reversal in adhesion molecule profile is related to EGFR
signalling
A role for Cetrorelix in the stimulation of PKC activity was
determined by phosphorylation of the MARCKS substrate for
classical and novel PKC isoforms or by probing for generalised
increased phosphorylation of canonical PKC target serines
(Figure 3) (Fujise et al, 1994; Nishikawa et al, 1997). This was
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Figure 1 Expression levels were measured as the mean of per cent positive fluorescence at time zero7s.e.m. at various time intervals. (A) DU-145 WT
cells labelled with FITC-conjugated anti-EGFR were analysed by flow cytometry. (B) DU-145 WT cells labelled with FITC-conjugated anti-E-cadherin were
analysed by flow cytometry. (C) DU-145 WT cells labelled with FITC-conjugated anti-b-catenin were analysed by flow cytometry. (D) DU-145 WT cells
labelled with FITC-conjugated anti-a-catenin were analysed by flow cytometry. (E) DU-145 WT cells labelled with FITC-conjugated anti-p120 were analysed
by flow cytometry. Data are the mean7s.e.m. of three experiments each performed in triplicate. *Po0.05 compared to untreated.
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inhibitor (Wells et al, 2002), to prevent such phosphorylation (data
not shown).
If Cetrorelix acts via PKC-mediated attenuation of EGFR
signalling, then an EGFR variant lacking the PKC target site
should be resistant. We utilised a DU-145 subline expressing an
EGFR construct in which the target PKC site, threonine 654, was
replaced by an alanine (DU-145 A654). Since Cetrorelix decreased
EGFR surface levels (Figure 1A) and increased surface levels and
protein levels of cell adhesion molecules (Figures 1B–E and 2),
cells expressing this EGFR A654 construct should be at least partly
resistant to Cetrorelix. Through the use of immunoblotting
techniques, we examined the protein levels of the cell adhesion
molecules after 24h of Cetrorelix exposure. Phosphorylated and
total EGFR levels, as well as total E-cadherin and b-catenin levels
were not extensively altered in the DU-145 A654 cells when
compared to changes observed in DU-145 WT cells (Figure 4).
These findings indicate that direct abrogation of EGFR signalling
by various means should yield a similar increase in E-cadherin and
b-catenin levels. Both the specific tyrosine kinase inhibitor
PD153035 and the anti-EGFR antibody (mb528) increased E-
cadherin and b-catenin levels similarly to those observed in DU-
145 WT after Cetrorelix treatment (Figure 5A and B). Finally,
exposure of DU-145 WT cells to EGFR siRNA resulted in the
downregulation of EGFR levels and an increase in E-cadherin
levels when compared to cells exposed to the nonrelevant siGFP
(Figure 5C).
−
−−
−
E-cadherin 
Puromycin 
Cetrorelix  
(10−5 M) 
 -Catenin 
-Actin 
++
+ +
Figure 2 DU-145 WT cells were challenged with 7puromycin (40mM)
in the presence of Cetrorelix (10
 5 M) for 24h. Lysates were collected and
separated by SDS–PAGE, transferred, and immunoblotted with antibody
to E-cadherin, antibody to b-catenin, or antibody to the loading control
b-actin. Shown are representative blots of two experiments.
 p-MARCKS 
p-Serine  
(PKC subsrate)
Cetrorelix 
105 kDa 
50 kDa 
_
_
_
75 kDa 
 -Actin 
h h h h min
PMA 4 3 2 1 30 0
Figure 3 Top immunoblot: DU-145 WT cells were exposed to
Cetrorelix (10
 5 M) from 30min to 4h. Lysates were collected and
separated by SDS–PAGE, transferred, and immunoblotted with antibody
recognising phosphorylated MARCKS. Bottom immunoblot: DU-145 WT
cells were challenged and immunoblotted with antibody recognising
phosphorylated serine in the context of canonical PKC target sites. The
bottom immunoblot demonstrates loading control of b-actin. Increases
observed in the top two immunoblots are comparable to PMA-positive
control. Shown are representative blots of three experiments.
DU-145 A654  DU-145 WT
p-EGFR 
EGFR 
E-cadherin 
 -Catenin 
-Actin
Cetrorelix (h)  0 6 12 24 0 6 12 24
Figure 4 DU-145 WT (left immunoblots) and A654 (right immuno-
blots) cells were exposed to Cetrorelix (10
 5 M) for up to 24h. Lysates
were collected and separated by SDS–PAGE, transferred, and immuno-
blotted with antibodies to p-EGFR, EGFR, E-cadherin, and b-catenin. Similar
data were seen with a-catenin and p120 (data not shown). Shown are
representative examples of three experiments.
DU-145 WT  
DU-145 WT PD153035
E-cadherin 
 -Catenin 
-Actin
DU-145 WT mb528 
  siGFP 
EGFR 
E-cadherin 
GAPDH
0 6 12 24
0 6 12 24
A
B
C
siEGFR
Figure 5 (A) DU-145 WT cells were exposed to PD153035 for 6, 12,
and 24h. (B) DU-145 WT cells were exposed to monoclonal antibody
(528) against EGFR for 6, 12, and 24h. (C) The EGFR siRNA was exposed
to cells for 24h and compared to the GFP siRNA. Lysates were collected
and separated by SDS–PAGE, transferred, and immunoblotted with
antibodies recognising EGFR, E-cadherin and b-catenin. Both b-actin and
GAPDH were used as loading controls. One of two experiments for each
point is shown.
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The functional consequences of EGFR signalling crossattenuation
by Cetrorelix extend to the invasive potential of the prostate
carcinoma cells. While Cetrorelix significantly reduced the
invasiveness of the DU-145 parental and WT cells, the invasiveness
of DU-145 A654 was limited to a lesser extent (Figure 6; Po0.05,
comparing Matrigel invasion after Cetrorelix treatment of DU-145
A654 and WT cells). These findings suggest that the effects of
Cetrorelix on both cell–cell adhesion molecules and cell invasive-
ness are mediated through its interference with the EGFR
signalling cascade.
Cetrorelix exposure increases cell–cell aggregation
To further assess the functional consequences of the concurrent
Cetrorelix-related decrease in EGFR levels and the increase in E-
cadherin and its associated proteins observed in the DU-145 WT
subline, a calcium-dependent aggregation assay was used after 48h
of Cetrorelix exposure (Figure 7). In these experiments, the
aggregation index of DU-145 WT and A654 cells treated with
Cetrorelix was compared to that of nontreated cells. We observed
that DU-145 WT cells exposed to Cetrorelix formed significantly
more cell–cell aggregates compared to either nontreated WT cells
or treated and nontreated A654 cells, while Cetrorelix-induced DU-
145 A654 aggregation was indistinguishable from nontreated cells
(Figure 7; Po0.05). We were also able to see similar results when
we exposed DU-145 WT cells to PD153035 to block EGFR
signalling (Figure 7B; Po0.05%).
Cell–cell aggregation requires E-cadherin to be present on the
cell surface and its associate molecules at the inner face of the
plasma membrane. In DU-145 WT cells, these adhesion complex
molecules were distributed throughout the cytosol (Figure 8).
Upon Cetrorelix treatment, not only did the levels increase, but
also the molecules were redistributed to the cells’ periphery; this
was particularly evident at sites of cell–cell contacts, regardless of
the degree of cell confluence. In aggregate, these data further
confirmed with functional application that the increases observed
in E-cadherin, a-and b-catenins, and p120 levels in Cetrorelix-
exposed DU-145 WT cells are the results of a reversal of the cells
invasive phenotype to one that resembles a more normal
phenotype and that Cetrorelix exerts at least some of its effects
via abrogation of autocrine EGFR cell signalling.
DISCUSSION
The LHRH analogue Cetrorelix is undergoing evaluation for
prostate cancer treatment. While initially considered for treatment
due to its central androgen suppression mechanism, direct cancer
cell efficacy has been shown. Cetrorelix has been demonstrated to
limit proliferation of a variety of human cancer cell lines, including
breast, ovarian, endometrial (Yap et al, 1997; Schally, 1999), and
prostate cancer cell lines (Qayum et al, 1990; Halmos et al, 2000).
Herein, we examined whether Cetrorelix altered an important
phenotype of tumour cells, decreased cell–cell adhesion. We found
that Cetrorelix exposure increased the levels of cell adhesion
molecules and enhanced the resultant cell–cell adhesion. Further-
more, Cetrorelix appears to function, at least in part, by
crossattenuation of signalling from the EGFR.
Several studies have long established that the loss of the
homotypic E-cadherin binding machinery correlates with an
invasive phenotype in prostate carcinomas (Behrens et al, 1989;
Vleminckx et al, 1991; Bussemakers et al, 1992). Thus, it is
logical that this cell–cell zipper would disappear concomitant
with increased cellular invasion (Shibata et al, 1994). This
disappearance of E-cadherin and/or any of the major adhesion
components affiliated with it is noted in most advanced carcinoma
cells (Takeichi, 1977; Hazan and Norton, 1998; Takeda et al,
1999). In fact, re-expression of E-cadherin has been shown to
reduce the tumorigenicity of some carcinoma cell lines (Jawhari
et al, 1999; Lowy et al, 2002). Interestingly, Cetrorelix exposure
increases the levels of all of the major adhesion molecules probed;
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Figure 6 Cetrorelix reduced the invasiveness of the DU-145 parental
(&) and DU-145 WT ( ) cells while only partly affecting that of DU-145
A654 ( ) cells. Invasiveness was measured by the cells’ ability to
transmigrate the extracellular matrix, Matrigel, in a Boyden Chamber assay.
Data are the mean7s.e.m. (n¼4). *Po0.05, Cetrorelix-treated (48h)
groups vs controls (diluent only), without drug; also Po0.05 between the
extent of decreased invasiveness of WT and A654 cells in the presence of
Cetrorelix.
0 50 100 150 200
+
Aggregation index
0 50 100 150 200
Aggregation index
* a
+
P
D
1
5
3
0
3
5
*
−
−
A
B
Figure 7 (A) Cetrorelix increased the cell–cell aggregation of the DU-
145 WT ( ) cells after 48h of exposure, while not affecting DU-145 A654
( ) cells. (B) The EGFR inhibitor PD153035 increased the cell–cell
aggregation of the DU-145 WT after 48h of exposure. Results are
expressed as the mean of the index of the degree of aggregation vs time
zero7s.e.m. at 1h (n¼3, each in triplicate). *Po0.05, Cetrorelix-treated
(þ) groups vs controls ( ), without drug.
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sthis could be secondary to either increased transcription or
decreased degradation. This should subsequently lead to the
reforming of the zipper. This was corroborated in our invasion
(Figure 6) and aggregation studies (Figure 7A and B) where, after
extended Cetrorelix exposure, the highly invasive WT cell line
became less invasive and aggregated to a greater extent than
nontreated cells.
The ability to exploit the findings that Cetrorelix treatment
increases both cell–cell adhesion and the levels of the key
molecules involved in the adhesion process is vastly improved
by defining the underlying basis for this occurrence. Other
LHRH analogues have been shown to limit prostate carcinoma
cell growth secondary to downregulation of EGFR (Moretti et al,
1996; Jungwirth et al, 1997a,b) or through interference with
signalling pathways initiated by the EGFR (Wells et al, 2002).
This occurred via PKC-mediated crossattenuation (Wells et al,
2002) secondary to phosphorylation on threonine 654 of EGFR
(Lin et al, 1986; Welsh et al, 1991). In this study, we show
direct activation of PKC substrate MARCKS by LHRH receptors
in a time-dependent manner (Figure 3). These findings led
us to believe that DU-145 cells engineered to express the PKC-
resistant A654 EGFR should be impervious to Cetrorelix treatment.
This was borne out by our findings that EGFR levels remained high
and cell adhesion molecule levels low in these cells in the face
of Cetrorelix exposure (Figure 4). The importance of EGFR
signalling was further demonstrated in a time-dependent manner
from the exposure of the DU-145 WT subline to an EGFR-specific
tyrosine kinase inhibitor, PD153035, and a monoclonal anti-
body against EGFR (mb528) (Figure 5A and B). Cetrorelix
and PD153035 both increased cell–cell adhesion in DU-145
WT, but had little effect on DU-A654 cells (Figure 7). The results
of all of our findings taken together indicate that the ability
of the LHRH analogue Cetrorelix to alter the adhesive profile of
these cells is at least partly mediated through altered EGFR
signalling.
That Cetrorelix restores cell–cell adhesion secondary to
disrupting EGFR signalling would be supported if EGFR signalling
could be shown to downregulate cell–cell adhesion. This was
shown to occur at least in the DU-145 WT cells by their increased
aggregation upon disruption of autocrine EGFR signalling
(Figure 7). Epidermal growth factor receptor signalling, upregu-
lated in an autocrine manner in prostate carcinomas (Kim et al,
1999), was shown to be responsible, at least in part, for the
downregulation of cadherin-mediated adhesion and levels of
molecules noted in these tumours as it is in many other
carcinomas (Sorscher et al, 1995a,b; Wilding et al, 1996; Jawhari
E-cadherin 
 -Catenin 
-Catenin 
p120 
0 h 24 h 48 h 48 h diluent only
Figure 8 Cells were exposed to Cetrorelix for up to 48h prior to immunofluorescent localisation of E-cadherin (top panels), a- and b-catenins (second
and third panels, respectively), or p120 (bottom panels) and compared to 48h diluent alone (right panel). Shown are representative photomicrographso f
two independent experiments; the target molecules are green and nuclei are red.
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set al, 1999; Andl et al, 2003). Another report indicated that EGFR
downregulation resulted in decreasing E-cadherin and catenins in
ovarian carcinoma cells (Alper et al, 2000). Although the reason
for this opposite effect in these cells was not obvious, it may be
related to the distinct nature of some ovarian cell types.
Presumably, such a reduction in the levels of adhesion molecules
plays a major role in prostate cancer progression (Wells, 2000).
How EGFR signalling limits cadherin-mediated adhesions is still
being deciphered (Ackland et al, 2003; Cozzolino et al, 2003).
However, this appears to involve both acute phosphorylation of
PKC and the dissociation and subsequent degradation of key
adhesion components. Regardless of the actual mechanism, the
end result is witnessed in the long-term downregulation of these
molecules.
In summary, we found that Cetrorelix restored the adhesiveness
of the human prostate carcinoma cells (and significantly inhibited
cellular proliferation) at similarly high pharmacologic doses used
by others (Jungwirth et al, 1997a; Tang et al, 2002). Additionally,
the LHRH agonist Zoladex was shown to only inhibit in vitro cell
proliferation of androgen-dependent (LNCaP) and androgen-
independent (DU-145) cell lines at similarly high concentrations
(Moretti et al, 1996; Wells et al, 2002). Thus it seems that higher
concentrations of LHRH analogues are needed to accomplish
direct cell growth inhibition than to achieve androgen suppression.
There are obvious speculative reasons for this, but regardless of
the mechanism, these studies serve as proofs of concepts that this
signalling axis can be exploited to limit prostate tumour
progression. It remains to be determined whether therapeutic
interventions will exploit this using higher affinity analogues or
indirect augmentation of the described pathway that cross-
attenuates the autocrine EGFR signalling pathway in tumour
promotion.
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